Adcentrx: new linker-payload combos for improved ADC therapeutic windows

Adcentrx emerged late Wednesday with a CBC-led $50 million series A round and a team of Sorrento veterans to advance a quartet of preclinical ADCs for solid tumors that incorporate internally developed linkers and payloads that could improve overall product profiles.

The San Diego- and Shanghai-based newco was founded in January by President and CEO Hui Li, who was CEO of Levena Biopharma, a Sorrento Therapeutics Inc. (NASDAQ:SRNE) subsidiary focused on n ADC therapies. Li was also Sorrento SVP of BD and general manager of China operations...